Dear Investors,

Opus8 and New York Private Equity Forums (NYPEF) are hosting an in-person, invitation-only private investor briefing featuring ColdSnap, a company redefining how frozen treats are produced and served through its proprietary rapid-freezing technology.

Company Overview

ColdSnap has developed a commercial-grade countertop appliance that instantly creates premium frozen treats: ice cream, frozen coffee, smoothies, and protein shakes—from shelf-stable pods. By eliminating the need for refrigeration, storage, and traditional supply chains, the company enables on-demand, single-serve production with minimal waste. Positioned at the intersection of food tech and convenience, ColdSnap targets high-traffic commercial environments with a scalable, asset-light model.

What Differentiates ColdSnap

• Instant, On-Demand Production — Delivers frozen products in under two minutes with no prep or cleanup

• No Cold Chain Required — Shelf-stable pods remove the need for freezing, storage, and spoilage concerns

• Versatile Platform — Supports a wide range of products including ice cream, frozen beverages, and nutritional shakes

• Commercial Scalability — Designed for offices, hospitality, healthcare, and foodservice environments

• Recurring Revenue Model — Razor-and-blade model driven by high-margin consumable pods

• Proven Leadership — Led by a team with deep experience in consumer appliances and food innovation

Event Details:

Date: May 1

Time: 11:30 am

Location: Online via Zoom

For more information about ColdSnap, visit their website: https://coldsnap.com/

​Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.

​Request investor materials by contacting Avery North at anorth@opus8.com.

​Thanks much and all the best,

Tien Wong

CEO

​​Opus8, Inc.

InventWood Confidential Investor Update - Virtual

by CONNECTpreneur Investor Network

WEDNESDAY, April 29, 12:00 pm EDT

Dear Investors:

Opus8 and NYPEF are hosting a small, invitation-only confidential investor update call featuring InventWood, a materials company commercializing SUPERWOOD™, a biomaterial delivering the strength of steel with the aesthetics of wood.

This closed-door session provides direct access to leadership and a focused discussion of the company’s proprietary platform, early commercial traction, manufacturing scale-up, and current financing opportunities for accredited investors.

InventWood is entering a key value-creation phase with automated manufacturing live, shipments underway, and accelerating demand as steel and concrete face rising costs and constraints.

Company Overview

InventWood has commercialized SUPERWOOD™, a structural biomaterial that is stronger than steel, significantly lighter, fire resistant, and carbon sequestering. Its proprietary process transforms wood by eliminating defects and increasing intrinsic strength and durability.

The company is entering through premium building applications and expanding toward large structural and infrastructure markets.

What Differentiates InventWood

• Category-Defining Material — Steel-level strength at a fraction of the weight
• Proprietary Platform — Molecular re-engineering of wood
• Commercialization Underway — Manufacturing live, shipments in market
• Defensible IP — 140+ patents
• Capital-Efficient Scale-Up — Premium markets fund expansion
• Large Market Pull — $750B+ addressable markets

Event Details

Date: Wednesday, April 29, 2026
Time: 12 pm EDT
Location: Online via Zoom

Attendance is strictly limited and curated.

Important Notes

This meeting is for DIRECT, ACTIVE and ACCREDITED private investors only. All attendees must pre-register via this Eventbrite page and complete the investor qualification criteria. All RSVPs are subject to review and approval.

Attendees must sign an NDA before the meeting.

To request investor materials in advance, please contact:
Avery North — anorth@opus8.com

Best,
Tien Wong
CEO, Opus8, Inc.
twong@opus8.com

Dear Investors,

Opus8 and New York Private Equity Forums (NYPEF) are hosting an in-person, invitation-only private investor briefing featuring ColdSnap, a company redefining how frozen treats are produced and served through its proprietary rapid-freezing technology.

Company Overview

ColdSnap has developed a commercial-grade countertop appliance that instantly creates premium frozen treats: ice cream, frozen coffee, smoothies, and protein shakes—from shelf-stable pods. By eliminating the need for refrigeration, storage, and traditional supply chains, the company enables on-demand, single-serve production with minimal waste. Positioned at the intersection of food tech and convenience, ColdSnap targets high-traffic commercial environments with a scalable, asset-light model.

What Differentiates ColdSnap

• Instant, On-Demand Production — Delivers frozen products in under two minutes with no prep or cleanup

• No Cold Chain Required — Shelf-stable pods remove the need for freezing, storage, and spoilage concerns

• Versatile Platform — Supports a wide range of products including ice cream, frozen beverages, and nutritional shakes

• Commercial Scalability — Designed for offices, hospitality, healthcare, and foodservice environments

• Recurring Revenue Model — Razor-and-blade model driven by high-margin consumable pods

• Proven Leadership — Led by a team with deep experience in consumer appliances and food innovation

Event Details:

Date: April 23

Time: 5:30 pm

Location: Bad Roman

10 Columbus Circle, Third Floor

New York, NY

For more information about ColdSnap, visit their website: https://coldsnap.com/

​Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.

​Request investor materials by contacting Avery North at anorth@opus8.com.

​Thanks much and all the best,

Tien Wong

CEO

​​Opus8, Inc.

ARC Medical Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

TUESDAY, April 21, 11:30 am EDT

​Dear Investors:

​Please join us for an invitation only virtual private investor meeting on Zoom, featuring ARC Medical, on Tuesday, April 21, 2026.

​This session is hosted by Opus8 in collaboration with the New York Private Equity Forums (NYPEF).

​ARC is one of the most exciting life sciences companies we have seen! ARC significantly improves surgical patient recovery by preventing internal adhesions, the most common complication in knee, shoulder, gynecological and abdominal surgeries.

​Key Investment Considerations

• ​Massive Markets: 11 million patients yearly and a TAM $11 billion

• ​Excellent Efficacy and Clinical Data: for company’s lead products for knee and shoulder surgeries

• ​Strong IP Provide Exclusivity: multiple patents granted that provide exclusivity for the company’s products through 2039 and beyond.

• ​Great Fundrasing traction: ARC has already raised $39 million ($21M in equity and $18M in non-dilutive revenue and grants), and will close the current round in a matter of weeks.

• ​Unicorn-level Exit Potential: representing a 20X return based on comparable companies in the wound healing arena.

• ​World Class Team: has designed, developed multi $billion products for companies including J&J, Stryker, Smith+Nephew, Amgen and Moderna

​Event Details:

​Date: April 21

​Time: 11:30 AM EDT

​Location: Online via Zoom

​Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.

​Request investor materials by contacting Avery North at anorth@opus8.com

​Thanks much and all the best,

​Tien Wong

​CEO

​Opus8, Inc.

​twong@opus8.com

CONNECTpreneur Forums are bi-monthly in person networking mashups, which have been attended by over 35,000 business leaders over the past 14 years.

Space is very limited at this venue, and this will another Sold Out in person event, so there will be no on-site registration.

All attendees must be pre-registered.

Program Highlights:

- We are capping attendance at 180+ business leaders, including 75+ angels and private investors, family offices, etc.

- Showcase of Emerging tech companies: A dedicated session for companies to showcase their groundbreaking ideas and innovations to a captivated audience of investors and industry experts.

- Heavy networking before, during, and after the event

Beverages and light fare will be provided.

i-Lumen Scientific Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

TUESDAY, April 14, 11:30 am EDT

Dear Investors,

​Opus8 is hosting a virtual, invitation-only private investor briefing featuring i-Lumen Scientific, an ophthalmology company developing a non-invasive treatment designed to restore vision in patients with Dry Age-Related Macular Degeneration (Dry-AMD).

​​This session is hosted by Opus8 in collaboration with the New York Private Equity Forums (NYPEF).

​Company Overview
i-Lumen is advancing a non-invasive, physician-delivered therapy designed to restore vision in Dry-AMD patients, with clinical data demonstrating meaningful improvement. Operating in a large, underserved market, the company is positioned for near-term value inflection through its pivotal trial and planned FDA pathway.

​What Differentiates i-Lumen
• Demonstrated Clinical Results — Patients showed meaningful vision improvement with sustained outcomes
• Non-Invasive Approach — Physician-delivered therapy designed to restore, not just preserve, vision
• Large Market Opportunity — 200M+ patients globally, with significant unmet need
• Strategic Positioning — Strong acquisition precedent in ophthalmology, including recent $850M transaction
• Active Raise — Currently raising a $35M Series B, with $18M already committed

​Event Details:
Date: Tuesday, April 14
Time: 11:30 AM EDT
Location: Online via Zoom

​Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.

​Request investor materials by contacting Avery North at anorth@opus8.com.

​Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.

NeuroEM Therapeutics Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

THURSDAY, April 2, 11:30 am EDT

Dear Investors,

Opus8 is hosting a virtual, invitation-only private investor briefing featuring NeuroEM, a medical technology company developing a non-invasive treatment designed to slow and potentially reverse the effects of Alzheimer’s disease.

NeuroEM’s patented TEMT-RF (Transcranial Electro-Magnetic Treatment using Radio Frequencies) platform targets the underlying biological drivers of Alzheimer’s by reducing toxic protein buildup, decreasing inflammation, and restoring cellular energy in the brain. The company’s device has received FDA Breakthrough Device designation, positioning it at the forefront of next-generation neurological therapeutics.

Company Overview

NeuroEM is advancing a clinically validated, non-pharmaceutical treatment approach for Alzheimer’s disease—one of the largest and fastest-growing healthcare challenges globally. Built on more than a decade of university research and supported by NIH funding, NeuroEM’s technology has demonstrated measurable cognitive improvement in early clinical trials and is designed to deliver scalable, at-home treatment for millions of patients.

What Differentiates NeuroEM

• Breakthrough Clinical Results — In early clinical trials, 7 of 8 Alzheimer’s patients showed measurable cognitive improvement within two months of treatment
• Strong Scientific Foundation — 10+ years of university research, supported by two NIH grants and extensive peer-reviewed validation
• Robust Intellectual Property — 9 issued patents with 10 additional patents pending worldwide
• Massive Market Opportunity — Alzheimer’s affects 55M+ patients globally, representing a healthcare market exceeding $300B annually
• Capital Efficient Growth — Currently raising a $5M Seed Preferred round at a $15M pre-money valuation, with a planned $5–10M Series A

Event Details:

Date: Thursday, April 2

Time: 11:30 AM EDT

Location: Online via Zoom

Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.

Request investor materials by contacting Avery North at anorth@opus8.com

Thanks much and all the best,

Tien Wong

CEO,

Opus8, Inc.

ARC Medical Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

THURSDAY, March 5, 1:00 pm EST

Please join us for an invitation only virtual private investor meeting on Zoom, featuring ARC Medical, on Tuesday, March 3`1st, 2026.

ARC is one of the most exciting life sciences companies we have seen! ARC significantly improves surgical patient recovery by preventing internal adhesions, the most common complication in knee, shoulder, gynecological and abdominal surgeries.

Key Investment Considerations

• Massive Markets: 11 million patients yearly and a TAM $11 billion

• Excellent Efficacy and Clinical Data: for company’s lead products for knee and shoulder surgeries

• Strong IP Provide Exclusivity: multiple patents granted that provide exclusivity for the company’s products through 2039 and beyond.

• Great Fundrasing traction: ARC has already raised $39 million ($21M in equity and $18M in non-dilutive revenue and grants), and will close the current round in a matter of weeks.

• Unicorn-level Exit Potential: representing a 20X return based on comparable companies in the wound healing arena.

• World Class Team: has designed, developed multi $billion products for companies including J&J, Stryker, Smith+Nephew, Amgen and Moderna

Event Details:

Date: March 31

Time: 11:30 AM EDT

Location: Online via Zoom

Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.

Request investor materials by contacting Avery North at anorth@opus8.com

Thanks much and all the best,

Tien Wong

CEO,

Opus8, Inc.

twong@opus8.com

Intrommune Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

MONDAY, March 23, 11:30 am EDT

Dear Investors,

Opus8 is hosting a virtual, invitation-only private investor briefing featuring Intrommune, a consumer health company pioneering a new approach to peanut allergy prevention.

Intrommune’s patented platform delivers allergens through a familiar daily routine—brushing your teeth. By administering controlled exposure through toothpaste, the technology trains the immune system and aims to prevent life-threatening peanut allergies through a simple, consumer-friendly delivery method.

Company Overview

Intrommune is developing a consumer-grade immunotherapy platform designed to make allergy prevention safe, simple, and scalable. By combining biotech-grade science with a routine daily behavior, the company is creating a new category in preventive allergy care. With early clinical validation and commercial traction already underway, Intrommune is positioned at the intersection of healthcare innovation and consumer accessibility.

What Differentiates Intrommune

• Clinically Validated Approach — In the Phase 1 peanut allergy study, patients achieved 97% adherence with zero dropouts and zero cases of anaphylaxis

• Early Commercial Traction — The company began generating revenue through its distribution channels in November 2025

• Large and Underserved Market — More than 33 million Americans suffer from food allergies, with limited treatment options currently available

• First-Mover Consumer Platform — The only biotech-grade allergy immunotherapy delivered in a consumer-ready toothpaste format

• Experienced Leadership — Led by seasoned executives and advisors from across biotech, healthcare, and consumer health

Event Details:

Date: March 23

Time: 11:30 AM EDT

Location: Online via Zoom

Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.

Request investor materials by contacting Avery North at anorth@opus8.com

Thanks much and all the best,

Tien Wong

CEO,

Opus8, Inc.

twong@opus8.com

Saltenna Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

TUESDAY, March 17, 11:30 am EDT

Dear Investors:

Opus8 is hosting a virtual, invitation-only private investor briefing featuring Saltenna, a wireless communications company enabling high-bandwidth connectivity in oceans, ice, dense terrain, underground environments, and metal infrastructure—areas where traditional RF systems fail.

Using proprietary Surface Electromagnetic Wave technology, Saltenna transmits signals without line of sight, unlocking secure communications across the 80%+ of the Earth previously considered unreachable.

Company Overview

Saltenna has developed a patented wireless transmission platform designed for mission-critical environments across defense, subsea oil & gas, logistics, telecom, and smart infrastructure. Backed by strong government support and commercial engagement, the company is positioned as a first mover redefining access to the electromagnetic spectrum.

What Differentiates Saltenna

• Deep IP Portfolio — 4 patents granted, 21 pending, 100+ patentable technologies, with ongoing filings

• Government Validation — $7M+ in recent non-dilutive funding from DTRA, USSOCOM, U.S. Air Force, and U.S. Navy

• Commercial Engagement — Active programs with major oil & gas and maritime operators

• Massive Addressable Markets — Multi-trillion-dollar infrastructure sectors spanning defense, energy, logistics, telecom, and smart cities

Event Details:

Date: March 17

Time: 11:30 AM EDT

Location: Online via Zoom

Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.

Request investor materials by contacting Avery North at anorth@opus8.com

Thanks much and all the best,

Tien Wong

CEO,

Opus8, Inc.

twong@opus8.com

Dear Investors,

Opus8 is hosting an invitation-only virtual private investor briefing featuring Soteria Battery Innovation Group, a company delivering inherently safer lithium-ion batteries through a capital-light, licensing-driven business model.

This private session will provide an opportunity to review the company’s patented materials technology, consortium and licensing strategy, commercial traction with global partners, and upcoming milestones, as well as a discussion of current and future capital formation opportunities for accredited investors.

This session is hosted by Opus8 in collaboration with the New York Private Equity Forums (NYPEF).

Soteria is entering a critical value-creation phase as battery safety shifts from a “feature” to mandatory infrastructure across electric vehicles, aviation, grid storage, and consumer electronics.

Company Overview

Soteria delivers inherently safe battery technology by embedding proprietary, chemistry-agnostic materials inside the battery cell itself, addressing the root cause of lithium-ion battery fires.

The technology reduces battery fire incidents by 90–99% while also lowering battery weight and cost through a significant reduction in copper usage—without requiring changes to existing battery manufacturing processes. Soteria does not manufacture batteries; instead, it operates a scalable licensing and royalty model supported by a global consortium of industrial and strategic partners.

The solution is compatible with virtually all advanced lithium-ion battery chemistries and form factors.

What Differentiates Soteria

Materials-Level Safety Infrastructure — Addresses failure at the source rather than relying on monitoring or post-event mitigation

Chemistry-Agnostic & Manufacturing-Compatible — Integrates into existing battery supply chains without redesign

Capital-Light Licensing Model — Scales through partners rather than manufacturing intensity

Meaningful Cost & Weight Advantages — ~80% reduction in copper usage

Deep Industry Validation — Supported by a global consortium of 130+ active partners

Consortium participants include organizations such as NASA, Mercedes-Benz, Volkswagen, and Lenovo.

Event Details

Date: March 5, 2026

Time: 1:00 - 2:00 PM EST

Location: Online via Zoom

Attendance is strictly limited and curated.

Important Notes

Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.

To request investor materials in advance, please contact:

Avery North — anorth@opus8.com

If you have any questions, feel free to reach out to me directly. I hope you can join us.

Best,

Tien Wong

CEO

Opus8, Inc.

twong@opus8.com

InventWood Private Investor Briefing - DC

by CONNECTpreneur Investor Network

WEDNESDAY, March 4, 5:30 pm EST

Opus8 is hosting a small, invitation-only virtual private investor briefing featuring InventWood, a materials company commercializing SUPERWOOD™, a category-defining biomaterial that delivers the strength of steel with the soul of wood.

This closed-door session will provide direct access to InventWood’s leadership team and a focused discussion of the company’s proprietary materials platform, early commercial traction, manufacturing scale-up, and near-term growth opportunities, including current financing for accredited investors.

InventWood is entering a critical value-creation phase with automated commercial manufacturing live, customer shipments underway, and accelerating demand as steel, aluminum, and concrete face rising costs and structural constraints.

Company Overview

InventWood has commercialized SUPERWOOD™, a breakthrough structural biomaterial that is stronger than steel, significantly lighter, fire resistant, moisture resistant, and carbon sequestering. The company’s proprietary molecular re-engineering process fundamentally transforms wood by eliminating defects and dramatically increasing intrinsic strength and durability.

InventWood is entering the market through premium architectural and exterior building applications while building toward expansion into large structural and infrastructure markets under existing mass-timber codes.

What Differentiates InventWood

• Category-Defining Material — Steel-level strength with wood’s weight, aesthetics, and fire resistance
• Proprietary Platform — Molecular re-engineering that upgrades wood’s intrinsic performance
• Commercialization Underway — Automated SUPERMILL operational with shipments in market
• Defensible IP Position — 140+ issued and pending patents
• Capital-Efficient Scale-Up — Premium early markets fund broader structural expansion
• Large Market Pull — $750B+ addressable markets across construction and infrastructure

Event Details

Date: Thursday, February 26, 2026
Time: 5:30pm EST
Location:

The Capital Grille

200 Park Ave,

New York, NY 10166

Attendance is strictly limited and curated.

Important Notes

This meeting is for DIRECT and ACTIVE private investors only. All attendees must pre-register via this Eventbrite page and complete the investor qualification criteria. All RSVPs are subject to review and approval.

To request investor materials in advance, please contact:
Avery North — anorth@opus8.com

If you have any questions, feel free to reach out to me directly.
I hope you can join us for this private discussion.

Best,
Tien Wong
CEO, Opus8, Inc.
twong@opus8.com
M: 703-932-9191

Space Phoenix Systems Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

WEDNESDAY, March 4, 11:30 am EST

Dear Investors:

Opus8 is hosting a virtual, invitation-only private investor briefing featuring Space Phoenix Systems (SPS), a space logistics company building the infrastructure backbone for microgravity research and in-space manufacturing.

As in-space manufacturing accelerates, SPS lowers the cost and complexity of accessing low Earth orbit (LEO) through streamlined, end-to-end launch and return services—making space-based R&D and production more practical and scalable.

Company Overview

Space Phoenix Systems is developing a cargo-focused, high-cadence, on-demand space logistics fleet in North America. The company provides fully managed launch and return services designed specifically for microgravity research and in-space manufacturing.

By optimizing mission architecture and simplifying access to LEO, SPS enables scientific, government, and industrial customers to conduct space-based research and production more efficiently and cost-effectively.

What Differentiates Space Phoenix Systems

• Strong Market Traction — $300M pipeline, 9 signed LOIs, and a $105M confirmed U.S. government contract

• Cargo-Focused Logistics Model — Dedicated, on-demand space cargo services

• Return-Capable Infrastructure — Economical and reliable return-trip payload delivery

• End-to-End Mission Management — Fully managed solutions that reduce complexity and cost

Event Details:

Date: March 4

Time: 11:30 AM EST

Location: Online via Zoom

Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.

Request investor materials by contacting Avery North at anorth@opus8.com

Thanks much and all the best,

Tien Wong

CEO,

Opus8, Inc.

twong@opus8.com

InventWood Private Investor Briefing - NYC

by CONNECTpreneur Investor Network

THURSDAY, February 26, 5:30 pm EST

Opus8 is hosting a small, invitation-only virtual private investor briefing featuring InventWood, a materials company commercializing SUPERWOOD™, a category-defining biomaterial that delivers the strength of steel with the soul of wood.

This closed-door session will provide direct access to InventWood’s leadership team and a focused discussion of the company’s proprietary materials platform, early commercial traction, manufacturing scale-up, and near-term growth opportunities, including current financing for accredited investors.

This session is hosted by Opus8 in collaboration with the New York Private Equity Forums (NYPEF).

InventWood is entering a critical value-creation phase with automated commercial manufacturing live, customer shipments underway, and accelerating demand as steel, aluminum, and concrete face rising costs and structural constraints.

Company Overview

InventWood has commercialized SUPERWOOD™, a breakthrough structural biomaterial that is stronger than steel, significantly lighter, fire resistant, moisture resistant, and carbon sequestering. The company’s proprietary molecular re-engineering process fundamentally transforms wood by eliminating defects and dramatically increasing intrinsic strength and durability.

InventWood is entering the market through premium architectural and exterior building applications while building toward expansion into large structural and infrastructure markets under existing mass-timber codes.

What Differentiates InventWood

• Category-Defining Material — Steel-level strength with wood’s weight, aesthetics, and fire resistance
• Proprietary Platform — Molecular re-engineering that upgrades wood’s intrinsic performance
• Commercialization Underway — Automated SUPERMILL operational with shipments in market
• Defensible IP Position — 140+ issued and pending patents
• Capital-Efficient Scale-Up — Premium early markets fund broader structural expansion
• Large Market Pull — $750B+ addressable markets across construction and infrastructure

Event Details

Date: Thursday, February 26, 2026
Time: 5:30pm EST
Location: The Capital Grille

200 Park Ave,

New York, NY 10166

Attendance is strictly limited and curated.

Important Notes

This meeting is for DIRECT and ACTIVE private investors only. All attendees must pre-register via this Eventbrite page and complete the investor qualification criteria. All RSVPs are subject to review and approval.

To request investor materials in advance, please contact:
Avery North — anorth@opus8.com

If you have any questions, feel free to reach out to me directly.
I hope you can join us for this private discussion.

Best,
Tien Wong
CEO, Opus8, Inc.
twong@opus8.com
M: 703-932-9191

Alphyn Biologics Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

TUESDAY, February 24, 11am EST

Opus8 is hosting a small, invitation-only investor meeting featuring Alphyn Biologics, a late-clinical dermatology company entering Series B formation.

This closed-door session will provide direct access to the Alphyn management team and an opportunity to review recent clinical progress and upcoming milestones.

Company Overview

Alphyn Biologics is a late-clinical dermatology company developing patented, plant-derived topical therapeutics, led by a Phase 2a–completed asset in Atopic Dermatitis with additional pipeline programs including Molluscum Contagiosum Virus (MCV).

What Differentiates Alphyn

• Huge Market - Multi-target topical mechanism addressing multiple disease drivers

• Excellent Traction - Recently closed on $15 million Series A

• Strong safety and tolerability profile to date

• Patent protection in the U.S. and Europe extending to 2043

• Secured, regulatory-compliant raw material supply

Event Details

Date: Tuesday, February 24, 2026
Time: 11 AM EST
Location: Online via Zoom

Attendance is limited and curated.

Important Notes

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

To request investor materials, contact:
Avery North — anorth@opus8.com

Thanks much and all the best,

Tien Wong

CEO

Opus8, Inc.

InventWood Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

THURSDAY, February 19, 11:30 am EST

Opus8 is hosting a small, invitation-only virtual private investor briefing featuring InventWood, a materials company commercializing SUPERWOOD™, a category-defining biomaterial that delivers the strength of steel with the soul of wood.

This closed-door session will provide direct access to InventWood’s leadership team and a focused discussion of the company’s proprietary materials platform, early commercial traction, manufacturing scale-up, and near-term growth opportunities, including current financing for accredited investors.

This session is hosted by Opus8 in collaboration with the New York Private Equity Forums (NYPEF).

InventWood is entering a critical value-creation phase with automated commercial manufacturing live, customer shipments underway, and accelerating demand as steel, aluminum, and concrete face rising costs and structural constraints.

Company Overview

InventWood has commercialized SUPERWOOD™, a breakthrough structural biomaterial that is stronger than steel, significantly lighter, fire resistant, moisture resistant, and carbon sequestering. The company’s proprietary molecular re-engineering process fundamentally transforms wood by eliminating defects and dramatically increasing intrinsic strength and durability.

InventWood is entering the market through premium architectural and exterior building applications while building toward expansion into large structural and infrastructure markets under existing mass-timber codes.

What Differentiates InventWood

• Category-Defining Material — Steel-level strength with wood’s weight, aesthetics, and fire resistance
• Proprietary Platform — Molecular re-engineering that upgrades wood’s intrinsic performance
• Commercialization Underway — Automated SUPERMILL operational with shipments in market
• Defensible IP Position — 140+ issued and pending patents
• Capital-Efficient Scale-Up — Premium early markets fund broader structural expansion
• Large Market Pull — $750B+ addressable markets across construction and infrastructure

Event Details

Date: Thursday, February 19, 2026
Time: 11:30am EST
Location: Online via Zoom

Attendance is strictly limited and curated.

Important Notes

This meeting is for DIRECT and ACTIVE private investors only. All attendees must pre-register via this Eventbrite page and complete the investor qualification criteria. All RSVPs are subject to review and approval.

To request investor materials in advance, please contact:
Avery North — anorth@opus8.com

If you have any questions, feel free to reach out to me directly.
I hope you can join us for this private discussion.

Best,
Tien Wong
CEO, Opus8, Inc.
twong@opus8.com
M: 703-932-9191

Dear Investors:

Opus8 is hosting a virtual, invitation-only virtual private investor briefing featuring Maxwell Biosciences, a clinical-stage biotechnology company advancing a first-in-class Synthetic Immune System™ platform designed to transform the treatment of infectious diseases.

This closed-door session will provide direct access to Maxwell’s leadership team and an opportunity to review the company’s Claromer™ technology, extensive scientific and government validation, lead clinical strategy, and upcoming FDA milestones, as well as a discussion of current and future financing opportunities for accredited investors.

Maxwell is entering a critical value-creation phase, supported by strong Pre-IND FDA feedback and an anticipated IND submission in 2026, positioning the company for meaningful clinical and strategic inflection points. Maxwell is uniquely positioned at the intersection of antimicrobial resistance, biodefense preparedness, and next-generation anti-infectives—areas now prioritized by governments, regulators, and strategic pharma partners worldwide.

Company Overview
Maxwell Biosciences has developed an AI-driven drug discovery platform that creates synthetic small molecules designed to mimic LL-37, the human immune system’s primary antimicrobial peptide. Unlike traditional antibiotics, Maxwell’s Claromers™ are broadly effective against nearly all tested bacterial and fungal pathogens—including drug-resistant strains and biofilms—without inducing resistance.

The platform is supported by over $65 million in non-dilutive government grants and investor financing, more than 250 peer-reviewed scientific publications, and seven U.S. military Collaborative Research and Development Agreements. Maxwell’s lead clinical program is targeting Chronic Rhinosinusitis (CRS), with Phase 1 clinical trials anticipated in 2026.

What Differentiates Maxwell Biosciences
• First-in-Class Synthetic Immune System™ — Small molecules designed to replicate natural human immunity rather than target single pathogens
• Broad-Spectrum, Resistance-Free Activity — Demonstrated efficacy against hundreds of bacterial and fungal pathogens, including drug-resistant strains and biofilms
• AI-Driven Claromer™ Platform — Rapid creation of a scalable library of drug candidates across multiple infectious disease indications
• Strong Government & Military Validation — DARPA-seeded platform supported by $65M+ in non-dilutive funding and active U.S. defense and public health collaborations
• Compelling Regulatory & IP Profile — Encouraging FDA Pre-IND feedback, robust composition-of-matter patents, and high likelihood of Qualified Infectious Disease Product (QIDP) designation with extended market exclusivity
• Massive Market Opportunity — Positioned to address a global infectious disease market projected to exceed $190B, with platform-level expansion across pharma, government stockpiling, and strategic partnerships

Event Details
Date: Tuesday, February 17, 2026
Time: 11:30am - 12:30pm EST
Location: Online via Zoom

Attendance is strictly limited and curated.

Important Notes
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

To request investor materials in advance, please contact:
Skylar Rallison — srallison@opus8.com

If you have any questions, feel free to reach out to me directly. I hope you can join us for this important discussion.

Best,

Tien Wong
CEO, Opus8, Inc.
twong@opus8.com
M: 703-932-9191

Opus8 is hosting a small, invitation-only private investor briefing featuring Soteria Battery Innovation Group, a company delivering inherently safer lithium-ion batteries through a capital-light, licensing-driven business model.

This closed-door session will provide direct access to Soteria’s leadership team and an opportunity to review the company’s patented materials technology, consortium and licensing strategy, commercial traction with global partners, and upcoming milestones, as well as a discussion of current and future capital formation opportunities for accredited investors.

Soteria is entering a critical value-creation phase as battery safety shifts from a “feature” to mandatory infrastructureacross electric vehicles, aviation, grid storage, and consumer electronics.

Company Overview

Soteria delivers inherently safe battery technology by embedding proprietary, chemistry-agnostic materials inside the battery cell itself, addressing the root cause of lithium-ion battery fires.

The technology reduces battery fire incidents by 90–99% while also lowering battery weight and cost through a significant reduction in copper usage—without requiring changes to existing battery manufacturing processes. Soteria does not manufacture batteries; instead, it operates a scalable licensing and royalty model supported by a global consortium of industrial and strategic partners.

The solution is compatible with virtually all advanced lithium-ion battery chemistries and form factors.

What Differentiates Soteria

• Materials-Level Safety Infrastructure — Addresses failure at the source rather than relying on monitoring or post-event mitigation

• Chemistry-Agnostic & Manufacturing-Compatible — Integrates into existing battery supply chains without redesign

• Capital-Light Licensing Model — Scales through partners rather than manufacturing intensity

• Meaningful Cost & Weight Advantages — ~80% reduction in copper usage

• Deep Industry Validation — Supported by a global consortium of 130+ active partners

Consortium participants include organizations such as NASA, Mercedes-Benz, Volkswagen, and Lenovo.

Event Details

Date: February 12, 2026
Time: 5:30 - 7:30 PM PST
Location: Fleming’s Prime Steakhouse & Wine Bar

180 El Camino Real G-2,

Palo Alto, CA 94304

Attendance is strictly limited and curated.

Important Notes

• This meeting is intended for direct, active private investors and strategic capital only

• All attendees must pre-register via this Eventbrite page and complete investor qualification criteria

• All RSVPs are subject to review and approval

To request investor materials in advance, please contact:
Skylar Rallison — srallison@opus8.com

If you have any questions, feel free to reach out to me directly. I hope you can join us in Palo Alto.

Thanks much and all the best,

Tien Wong

CEO

Opus8, Inc.

twong@opus8.com

M 703 932 9191

Actuated Medical Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

WEDNESDAY, February 11, 11 am EST

Opus8 is hosting an invitation-only virtual private investor briefing featuring Actuated Medical, a medical device company transforming tools for brain access, biologic therapy delivery, & neural disease treatment.

You will be able to meet the Actuated Medical leadership team and will be given an opportunity to review the company’s neuro platform, clinical direction, and upcoming milestones, as well as its broader strategic roadmap.

Company Overview

Actuated Medical is a med device company transforming tools for brain access, biologic therapy delivery, & neural disease treatment. The company also maintains a portfolio of FDA-cleared technologies, providing strategic and financial optionality as it advances its core neuro program.

What Differentiates Actuated Medical

• Large Neurological Opportunity — Platform technology addressing significant unmet needs in neuro procedures

• Proprietary Engineering — Differentiated design enabling precision access and delivery

• Clinical Momentum — Active engagement with leading clinicians and academic medical centers

• Strategic Optionality — FDA-cleared assets alongside a focused neuro platform

• Experienced Leadership — Proven device development and commercialization expertise

Event Details

Date: Wednesday, February 11, 2026
Time: 11 AM – 12 PM EST
Location: Online via Zoom

Attendance is limited and curated.

Important Notes

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

To request investor materials, contact:
Avery North — anorth@opus8.com

Thanks much and all the best,

Tien Wong

CEO

Opus8, Inc.

Come join us in Baltimore, MD for a CONNECTpreneur Forum Event like you've never seen before! This event is set to be a smaller and more exclusive gathering, tailor-made for premium networking and connecting entrepreneurs with seasoned investors. With CONNECTpreneur's track record of fostering valuable connections and driving investment opportunities, attendees can expect an unparalleled platform to fuel their business growth.

Tickets will go FAST, as we only have a VERY limited number available!

CONNECTpreneur is a bi-monthly networking mashup, which has been attended by over 40,000 business leaders since 2011.

Space is very limited at this venue, and we expect another Sold Out crowd, so there will be no on-site registration.

All attendees must be pre-registered.

Continental breakfast and unlimited coffee will be provided.

Program Highlights:

- We are capping attendance at 200 business leaders, including 75+ angels and private investors, family offices, etc.

- Investor and VIP Speakers who are deeply rooted in our community, sharing their insider knowledge and showcasing the innovation thriving in our region.

- Heavy networking before, during, and after the event

Company Showcase:

We will have a Rocket Pitch session with emerging tech companies: a dedicated session for companies to showcase their groundbreaking ideas and innovations to a captivated audience of investors and industry experts.

Opus8 is hosting a small, invitation-only private investor briefing featuring Angiex, a clinical-stage oncology company advancing a first-in-class platform of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) for solid tumors.

This closed-door session will provide direct access to Angiex’s leadership team and an opportunity to review the company’s lead Phase 1 clinical program, emerging clinical signals, platform differentiation, and upcoming milestones, as well as a discussion of current financing opportunities for accredited investors.

Angiex is entering a critical value-creation phase, with early clinical data beginning to inform downstream strategic and capital formation decisions.

Company Overview

Angiex is developing a new class of antibody-drug conjugates designed to deliver therapeutic payloads directly to the nucleus of tumor cells and tumor-associated vasculature. The company’s lead asset, AGX101, targets TM4SF1, a protein highly expressed in tumor blood vessels and tumor cells, with limited expression in normal adult tissues.

AGX101 is currently in Phase 1 clinical trials in patients with advanced solid tumors and has demonstrated an exceptional safety profile alongside early signs of clinical activity, including stable disease and tumor shrinkage at higher dose levels.

What Differentiates Angiex

• First-in-Class Nuclear-Delivered ADC Platform — Designed to bypass traditional ADC resistance mechanisms through direct nuclear payload delivery
• Validated Tumor Target (TM4SF1) — Enables dual targeting of tumor vasculature and tumor cells
• Three Complementary Mechanisms of Action — Vascular deprivation, immune activation, and direct tumor cell killing
• Outstanding Safety Profile — No observed adverse effects in primate studies at the highest dose tested
• Early Clinical Validation — On-target pharmacodynamics and emerging tumor response in Phase 1

Event Details

Date: Tuesday, February 3, 2026
Time: 11:30 – 12:30 PM EST
Location: Online via Zoom

Attendance is strictly limited and curated.

Important Notes

This meeting is intended for direct and active private investors only.
All attendees must pre-register via this Eventbrite page and complete investor qualification criteria.
All RSVPs are subject to review and approval.

To request investor materials in advance, please contact:
Skylar Rallison — srallison@opus8.com

If you have any questions, feel free to reach out to me directly. I hope you can join us Monday evening.

Thanks much and all the best,

Tien Wong

CEO

Opus8, Inc.

twong@opus8.com

M 703 932 9191

Opus8 is hosting a small, invitation-only private investor briefing featuring Soteria Battery Innovation Group, a company delivering inherently safer lithium-ion batteries through a capital-light, licensing-driven business model.

This closed-door session will provide direct access to Soteria’s leadership team and an opportunity to review the company’s patented materials technology, consortium and licensing strategy, commercial traction with global partners, and upcoming milestones, as well as a discussion of current and future capital formation opportunities for accredited investors.

This session is hosted by Opus8 in collaboration with the New York Private Equity Forums (NYPEF).

Soteria is entering a critical value-creation phase as battery safety shifts from a “feature” to mandatory infrastructureacross electric vehicles, aviation, grid storage, and consumer electronics.

Company Overview

Soteria delivers inherently safe battery technology by embedding proprietary, chemistry-agnostic materials inside the battery cell itself, addressing the root cause of lithium-ion battery fires.

The technology reduces battery fire incidents by 90–99% while also lowering battery weight and cost through a significant reduction in copper usage—without requiring changes to existing battery manufacturing processes. Soteria does not manufacture batteries; instead, it operates a scalable licensing and royalty model supported by a global consortium of industrial and strategic partners.

The solution is compatible with virtually all advanced lithium-ion battery chemistries and form factors.

What Differentiates Soteria

• Materials-Level Safety Infrastructure — Addresses failure at the source rather than relying on monitoring or post-event mitigation

• Chemistry-Agnostic & Manufacturing-Compatible — Integrates into existing battery supply chains without redesign

• Capital-Light Licensing Model — Scales through partners rather than manufacturing intensity

• Meaningful Cost & Weight Advantages — ~80% reduction in copper usage

• Deep Industry Validation — Supported by a global consortium of 130+ active partners

Consortium participants include organizations such as NASA, Mercedes-Benz, Volkswagen, and Lenovo.

Event Details

Date: January 27, 202
Time: 5:30 - 7:30 PM EST
Location: The Capital Grille

200 Park Ave,

New York, NY 10166

Attendance is strictly limited and curated.

Important Notes

• This meeting is intended for direct, active private investors and strategic capital only

• All attendees must pre-register via this Eventbrite page and complete investor qualification criteria

• All RSVPs are subject to review and approval

To request investor materials in advance, please contact:
Skylar Rallison — srallison@opus8.com

If you have any questions, feel free to reach out to me directly. I hope you can join us in New York.Thanks much and all the best,

Tien Wong

CEO

Opus8, Inc.

twong@opus8.com

M 703 932 9191

Dear Investors:

Opus8 is hosting a virtual, invitation-only virtual private investor briefing featuring Maxwell Biosciences, a clinical-stage biotechnology company advancing a first-in-class Synthetic Immune System™ platform designed to transform the treatment of infectious diseases.

This closed-door session will provide direct access to Maxwell’s leadership team and an opportunity to review the company’s Claromer™ technology, extensive scientific and government validation, lead clinical strategy, and upcoming FDA milestones, as well as a discussion of current and future financing opportunities for accredited investors.

Maxwell is entering a critical value-creation phase, supported by strong Pre-IND FDA feedback and an anticipated IND submission in 2026, positioning the company for meaningful clinical and strategic inflection points. Maxwell is uniquely positioned at the intersection of antimicrobial resistance, biodefense preparedness, and next-generation anti-infectives—areas now prioritized by governments, regulators, and strategic pharma partners worldwide.

Company Overview
Maxwell Biosciences has developed an AI-driven drug discovery platform that creates synthetic small molecules designed to mimic LL-37, the human immune system’s primary antimicrobial peptide. Unlike traditional antibiotics, Maxwell’s Claromers™ are broadly effective against nearly all tested bacterial and fungal pathogens—including drug-resistant strains and biofilms—without inducing resistance.

The platform is supported by over $65 million in non-dilutive government grants and investor financing, more than 250 peer-reviewed scientific publications, and seven U.S. military Collaborative Research and Development Agreements. Maxwell’s lead clinical program is targeting Chronic Rhinosinusitis (CRS), with Phase 1 clinical trials anticipated in 2026.

What Differentiates Maxwell Biosciences
• First-in-Class Synthetic Immune System™ — Small molecules designed to replicate natural human immunity rather than target single pathogens
• Broad-Spectrum, Resistance-Free Activity — Demonstrated efficacy against hundreds of bacterial and fungal pathogens, including drug-resistant strains and biofilms
• AI-Driven Claromer™ Platform — Rapid creation of a scalable library of drug candidates across multiple infectious disease indications
• Strong Government & Military Validation — DARPA-seeded platform supported by $65M+ in non-dilutive funding and active U.S. defense and public health collaborations
• Compelling Regulatory & IP Profile — Encouraging FDA Pre-IND feedback, robust composition-of-matter patents, and high likelihood of Qualified Infectious Disease Product (QIDP) designation with extended market exclusivity
• Massive Market Opportunity — Positioned to address a global infectious disease market projected to exceed $190B, with platform-level expansion across pharma, government stockpiling, and strategic partnerships

Event Details
Date: Wednesday, January 21, 2026
Time: 11:30am - 12:30pm EST
Location: Online via Zoom

Attendance is strictly limited and curated.

Important Notes
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

To request investor materials in advance, please contact:
Skylar Rallison — srallison@opus8.com

If you have any questions, feel free to reach out to me directly. I hope you can join us for this important discussion.

Best,

Tien Wong
CEO, Opus8, Inc.
twong@opus8.com
M: 703-932-9191

Opus8 is hosting a small, invitation-only private investor briefing featuring Angiex, a clinical-stage oncology company advancing a first-in-class platform of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) for solid tumors.

This closed-door session will provide direct access to Angiex’s leadership team and an opportunity to review the company’s lead Phase 1 clinical program, emerging clinical signals, platform differentiation, and upcoming milestones, as well as a discussion of current financing opportunities for accredited investors.

Angiex is entering a critical value-creation phase, with early clinical data beginning to inform downstream strategic and capital formation decisions.

Company Overview

Angiex is developing a new class of antibody-drug conjugates designed to deliver therapeutic payloads directly to the nucleus of tumor cells and tumor-associated vasculature. The company’s lead asset, AGX101, targets TM4SF1, a protein highly expressed in tumor blood vessels and tumor cells, with limited expression in normal adult tissues.

AGX101 is currently in Phase 1 clinical trials in patients with advanced solid tumors and has demonstrated an exceptional safety profile alongside early signs of clinical activity, including stable disease and tumor shrinkage at higher dose levels.

What Differentiates Angiex

• First-in-Class Nuclear-Delivered ADC Platform — Designed to bypass traditional ADC resistance mechanisms through direct nuclear payload delivery
• Validated Tumor Target (TM4SF1) — Enables dual targeting of tumor vasculature and tumor cells
• Three Complementary Mechanisms of Action — Vascular deprivation, immune activation, and direct tumor cell killing
• Outstanding Safety Profile — No observed adverse effects in primate studies at the highest dose tested
• Early Clinical Validation — On-target pharmacodynamics and emerging tumor response in Phase 1

Event Details

Date: Monday, January 12, 2026
Time: 5:30 – 7:30 PM PST
Location: Fogo de Chão, 201 3rd Street, San Francisco

Attendance is strictly limited and curated.

Important Notes

This meeting is intended for direct and active private investors only.
All attendees must pre-register via this Eventbrite page and complete investor qualification criteria.
All RSVPs are subject to review and approval.

To request investor materials in advance, please contact:
Skylar Rallison — srallison@opus8.com

If you have any questions, feel free to reach out to me directly. I hope you can join us Monday evening.

Thanks much and all the best,

Tien Wong

CEO

Opus8, Inc.

twong@opus8.com

M 703 932 9191

Actuated Medical Private Investor Briefing - San Francisco

by CONNECTpreneur Investor Network

SUNDAY, January 11, 2 pm PST

Opus8 is hosting a small, invitation-only private investor briefing during JP Morgan Week featuring Actuated Medical, a medical device company transforming tools for brain access, biologic therapy delivery, & neural disease treatment.

This closed-door session will provide direct access to the Actuated Medical leadership team and an opportunity to review the company’s neuro platform, clinical direction, and upcoming milestones, as well as its broader strategic roadmap.

Company Overview

Actuated Medical is a med device company transforming tools for brain access, biologic therapy delivery, & neural disease treatment. The company also maintains a portfolio of FDA-cleared technologies, providing strategic and financial optionality as it advances its core neuro program.

What Differentiates Actuated Medical

• Large Neurological Opportunity — Platform technology addressing significant unmet needs in neuro procedures

• Proprietary Engineering — Differentiated catheter-based design enabling precision access and delivery

• Clinical Momentum — Active engagement with leading clinicians and academic medical centers

• Strategic Optionality — FDA-cleared assets alongside a focused neuro platform

• Experienced Leadership — Proven device development and commercialization expertise

Event Details

Date: Sunday, January 11, 2026
Time: 2 – 3:30 PM PST
Location: Fogo de Chão, San Francisco

Attendance is limited and curated.

Important Notes

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

If you have any questions, please reach out to me. Hope to see you on Jan 11th!

To request investor materials, contact:
Skylar Rallison — srallison@opus8.com

Thanks much and all the best,

Tien Wong

CEO

Opus8, Inc.

twong@opus8.com

M 703 932 9191

Kick Off JPM Week 2026 with an Exclusive Investor Networking Brunch!

Start your JPM Week experience with an exceptional networking opportunity designed to connect healthcare and life sciences investors with leading biotech and life sciences entrepreneurs.

Why Attend?

• Meet dozens of top-tier investors and influential industry leaders in an intimate, high-value setting.

• Connect with innovative companies driving breakthroughs in healthcare and biotech.

• Expand your network with like-minded professionals, entrepreneurs, and decision-makers.

Hosted annually by CONNECTpreneur and Opus8, this event offers an exclusive chance to build relationships that can shape the future of healthcare and life sciences.

Event Details

📅 Sunday, January 11, 2026

📍 Fogo de Chão Brazilian Steakhouse

201 3rd St Suite 100,

San Francisco, CA 94103

Enjoy light fare and unlimited premium coffee in a relaxed, upscale atmosphere.

Who Should Attend?

• VCs and Accredited investors passionate about healthcare, biotech, and life sciences.

• Entrepreneurs and founders seeking capital and partnerships.

Limited Availability!

This event is highly sought after, with limited spots available to ensure meaningful connections. Reserve your seat today before space runs out!

Take the First Step

Discover the partnerships and insights that could define your 2026.

Register Now to secure your spot and begin your JPM Week on the right note!

Sponsorship and Exhibitor Opportunities

Elevate your brand in front of a highly curated audience of investors and industry leaders. For more information, please contact Skylar Rallison at srallison@opus8.com.

Alphyn Biologics Private Investor Meeting - San Francisco

by CONNECTpreneur Investor Network

SUNDAY, January 11, 9:30am PST

Opus8 is hosting a small, invitation-only investor meeting during JPM Week featuring Alphyn Biologics, a late-clinical dermatology company entering Series B formation.

This closed-door session will provide direct access to the Alphyn management team and an opportunity to review recent clinical progress and upcoming milestones.

Company Overview

Alphyn Biologics is a late-clinical dermatology company developing patented, plant-derived topical therapeutics, led by a Phase 2a–completed asset in Atopic Dermatitis with additional pipeline programs including Molluscum Contagiosum Virus (MCV).

What Differentiates Alphyn

• Huge Market - Multi-target topical mechanism addressing multiple disease drivers

• Excellent Traction - Recently closed on $15 million Series A

• Strong safety and tolerability profile to date

• Patent protection in the U.S. and Europe extending to 2043

• Secured, regulatory-compliant raw material supply

Event Details

Date: Sunday, January 11
Time: 9:30 AM PST
Location: Fogo de Chão, San Francisco

Attendance is limited and curated.

Important Notes

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

To request investor materials, contact:
Skylar Rallison — srallison@opus8.com

Thanks much and all the best,

Tien Wong

CEO

Opus8, Inc.

Dear Investor Friends:

Please join us for this virtual investor-only meeting on Friday, December 19 featuring Intrommune, a consumer health company with a revolutionary approach to peanut allergy prevention.

Intrommune’s patented platform delivers allergens via a familiar routine: brushing your teeth. This toothpaste trains the immune system and helps prevent life-threatening nut allergies.

The Investment Opportunity:

• Amount: $4 million, first closing in December/January

• Minimum investment: $100,000

• Early investors receive preferential terms

• NASDAQ IPO targeted within 36 months

Key Investment Considerations:

Validated Science, Consumer Simplicity - In the Phase 1 study for peanut allergy, patients achieved 97% adherence with 0 dropouts and 0 cases of anaphylaxis

TRACTION - Company is already generating revenue through its distribution channels in November, 2025.

Enormous Market Need with 1st Mover Advantage - Over 33 million Americans suffer from food allergies, with limited treatment options. Intrommune is the only biotech-grade product in a consumer-ready delivery formar.

Attractive Investment Terms - Attractive valuation and terms with incentives.

World Class Leadership - Company is led by some of the top names in the industry

Event Details:

Location: Online via Zoom

Date: Friday, December 19 | 11:30am EST

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Don't miss out - RSVP now.

You can request investment materials by contacting Skylar Rallison at srallison@opus8.com

We look forward to hosting you and exploring this rare convergence of biotech innovation and consumer-scale opportunity.

All the best,

Tien Wong

CEO

Opus8, Inc.

Come join us in Tysons Corner, VA for a CONNECTpreneur Forum Event like you've never seen before!

CONNECTpreneur is a bi-monthly networking mashup, which has been attended by 30,000+ business leaders over the past 13 years and Is cited as "The Best Networking Events in the MidAtlantic" by independent media as well as over 70% of surveyed past attendees.

Space is very limited at this venue, and we expect another sold out crowd, so there will be no on-site registration.

All attendees must be pre-registered.

Program Highlights:

- Showcase of emerging tech companies: A dedicated session for companies to showcase their groundbreaking ideas and innovations to a captivated audience of investors and industry experts.

- We are capping attendance at 200 business leaders, including 75+ angels and private investors, family offices, etc.

- Speakers who are deeply rooted in our community, sharing their insider knowledge and showcasing the innovation thriving in our region.

- Heavy networking before, during, and after the event

Festive attire is encouraged!🎄

Back by popular demand! Join us for an exclusive CONNECTpreneur Master Class featuring Anthony Millin, CEO/Co-Founder of My NEXT Raise

When:

Thursday, December 11, 2025

11:30 am ET

Description:

In today’s fast-moving investment landscape, raising capital is more competitive than ever. Founders who succeed aren’t just lucky — they’re strategic, prepared, and investor-ready. Join Anthony Millin — a trusted authority with decades of experience as a venture investor, startup attorney, serial entrepreneur, and CEO/Co-Founder of My NEXT Raise — for this high-impact Masterclass. Anthony has raised capital himself, advised hundreds of founders, and built a platform designed specifically to help startups succeed.

In this session, you'll gain:

• Authority-backed insights from someone who’s been in the fundraising trenches — and won

• A behind-the-scenes look at what top investors actually look for (most founders miss this)

• Proven tools and strategies from My NEXT Raise, used by hundreds of successful startups

• A clear, step-by-step path to becoming investor-ready — with legal and business essentials aligned

• An opportunity to connect with Anthony and ask questions directly

• Access to exclusive fundraising tools — only available to attendees

Join us again to dive deeper into these critical issues and more as 2025 comes to a close. What will the fundraising market look like in 2026? How do founders need to adjust? Don’t miss this important Masterclass!

Whether you're preparing for your first seed round or scaling toward Series A, this session will arm you with the knowledge, credibility, and confidence to raise capital effectively — and close with conviction.